Home / Combinations / Hexarelin + Mod GRF 1-29
CombinationMuscle GrowthFat LossAnecdotal evidence
Hexarelin + Mod GRF 1-29
Anabolic GH Amplification
Hexarelin is one of the most potent synthetic GHRP compounds, associated with robust GH release and additional cardioprotective receptor activity. Mod GRF 1-29 (CJC-1295 without DAC) is a truncated GHRH analog that provides pulsatile GH stimulation without pituitary desensitization. This pairing is commonly researched for maximizing GH secretion through complementary GHRH and GHRP receptor activation.
Stack components
HexarelinCompound 01
CJC-1295 (without DAC)Compound 02
2
Compounds
2
Sources on file
13
Providers carry all
Mechanism
What each compound is researched for on its own. Nothing here describes an interaction between them.
Compound 01
Hexarelin
Potent synthetic GHRP that activates GHS-R1a and CD36 receptors, producing robust GH pulses alongside documented cardioprotective receptor activity.
Compound 02
CJC-1295 (without DAC)
Truncated GHRH analog (CJC-1295 without DAC) that drives pulsatile pituitary GH secretion with a short active window that preserves the natural GH rhythm.
Composition
2 compounds · 2 research areas
Stated as recorded. This page describes each compound separately and makes no claim that they act together.
Safety notes
Hexarelin is associated with transient increases in cortisol and prolactin at higher research doses; periodic cycling is commonly discussed in community research literature. Mod GRF 1-29's short half-life supports physiological GH pulsatility. No formal human combination trial exists.
Author-written. Not derived from any compound field, and not covered by the profile-integrity audit that gates the peptide pages.
Research references2 sources
Moderate
Hexarelin, a growth hormone-releasing peptide, directly stimulates pituitary somatotrophs in vitro
Endocrinology 1994
PeptideBase notePer-component source only — no combination study exists
no identifier on file
Moderate
Prolonged stimulation of GH and IGF-I secretion by CJC-1295
J Clin Endocrinol Metab 2006
PeptideBase noteRelated GHRH analog study — no Mod GRF 1-29 combination study exists
Related combinations3 share an area
Educational use only
PeptideBase documents what compounds are researched together and what evidence exists for each one separately. It does not provide medical advice, diagnosis, treatment, prescribing guidance or dosing instructions. Last reviewed 23 Apr 2026.
PeptideBase documents what compounds are researched together and what evidence exists for each one separately. It does not provide medical advice, diagnosis, treatment, prescribing guidance or dosing instructions. Last reviewed 23 Apr 2026.